Beijing Huamai Taikē Medical Devices Relaunches IPO on BSE with Innovative Vascular Intervention Portfolio

Jun 24, 2026 18:07 CST Updated 18:07

Percutek Therapeutics

Developer of Minimally Invasive Cardiovascular Treatment Devices

Device Home

Pioneer in Media Coverage of Medical Devices

Sharing Professional Medical Device Knowledge

Source:Device Home,Reproduction without authorization is prohibited, and may only be reproduced after 24 hours.

June 22,The Beijing Stock Exchange has officially acceptedIPO Application of Beijing Percutek Therapeutics Inc. (hereinafter referred to as “Percutek Therapeutics”)This also marks the company’s renewed pursuit of capital market access after terminating its application for listing on the STAR Market in 2022.

Screenshot fromPercutek Therapeutics: Beijing Stock Exchange Prospectus

Shifting Focus to the Beijing Stock Exchange

The Inflection Point in Performance Becomes the Core Bargaining Chip

The prospectus shows that,Percutek TherapeuticsThe number of shares to be publicly offered in this issuance shall not exceed 24 million shares (excluding the over-allotment option), or 27.6 million shares (if the over-allotment option is exercised in full).

The proposed fundraising amount is RMB 251 million, primarily intended for the new production base project for high-end medical devices and the construction of the R&D center.Of this amount, RMB 151 million was invested in a new production base for high-end medical devices, and RMB 100 million was allocated for the construction of an R&D center.

Screenshot fromPercutek Therapeutics BSE Prospectus

In terms of performance,Percutek Therapeutics inThe revenues for 2023, 2024, and 2025 were RMB 154 million, respectively,RMB 203 million,RMB 231 million,Net profit attributable to shareholders of the parent company were respectively-16.7635 million yuan,8.5308 million yuan,RMB 17.7485 million, with net profits excluding non-recurring items amounting to RMB -24.2603 million, RMB 10.0249 million, and RMB 12.6411 million, respectively.

Screenshot fromPercutek Therapeutics BSE Prospectus

Percutek Therapeutics stated,The Company’s accumulated uncovered deficits were primarily attributable to the increase in various expenses associated with the commercialization of products post-launch, as well as continued investment in research and development. The Company has achieved profitability in the past two years; its ability to sustain profitability in the future will depend mainly on the growth in revenue from existing products and the sales performance of products currently under development once they are successfully launched.

The industry also widely recognizes that,Percutek Therapeutics turned a profit in 2024, achieving a net profit of RMB 8.53 million, and doubled its net profit to RMB 17.7485 million in 2025, marking two consecutive years of profitability.

AndThis performance inflection point has also become the core bargaining chip for its IPO on the Beijing Stock Exchange.Previously, when the company applied for listing on the STAR Market in 2022,The company has consistently reported net losses. According to its prospectus at the time, cumulative losses from 2019 to June 2022 exceeded RMB 300 million.

Screenshot fromPercutek Therapeutics 2022 SSE Prospectus

Furthermore, from the perspective of equity structure, as of December 2025, this IPO on the Beijing Stock ExchangeChairman of Percutek TherapeuticsZhou Jian directly holds20.2948% equity interest. In addition,Zhou Jian also holds a total of approximately 13.5% equity interest through other companies,Therefore, Zhou Jian holds a total ofPercutek Therapeutics33.8097% equity interest, is theThe company's controlling shareholder and actual controller.

Screenshot fromPercutek Therapeutics: Prospectus for Listing on the Beijing Stock Exchange

Comprehensive Coverage of Vascular Intervention

Launch of Multiple "First-in-Class" Products

Data shows that,Percutek Therapeutics is a high-tech enterprise in China focused on the research, development, and application of innovative products and therapies in the field of vascular disease treatment. Its business involvesAortic, Peripheral and Coronary, Neurointerventional, and Access FieldsResearch, development, production, and sales of products, achievingComprehensive coverage of the entire vascular disease treatment business.

In the field of endovascular intervention for the aorta,Percutek TherapeuticsThe world’s first thoracic aortic stent graft specifically developed for the repair of aortic dissection with short landing zones，Suitable for short landing zones and large-angle aneurysms,Effectively expanded the indications for endovascular aortic repair.Furthermore, it is used forType A Aortic DissectionThe World's First Integrated Suture-Free Intravascular Stent System for Artificial Blood Vessels，Achieve Simplified and Innovative Surgical Techniques to Expand Surgical Accessibility.

In the field of peripheral and coronary vascular disease treatment,Percutek TherapeuticsLeveraging the mechanical vibration, cavitation, and shockwave effects of ultrasound, a series of ultrasonic catheter products has been developed, holding promise for achieving recanalization of total occlusions in peripheral and coronary arteries. Furthermore, the company has also laid out R&D efforts for multiple neurointerventional access products designed for the treatment of hemorrhagic and ischemic cerebrovascular diseases.

As of April 2026,Percutek TherapeuticsNineteen products have obtained the Chinese medical device registration certificate, and two products have received CE certification from the European Union.Meanwhile, the company also hasMore than ten products under development are in clinical trial and preclinical research stages, covering the fields of aortic, peripheral and coronary, neurointerventional, and access solutions.

——

Currently, with the rapid development of China’s domestic medical device industry in aortic, peripheral and coronary, and neurointerventional fields, competition within the sector has become increasingly intense. Among these, multinational medical device companies such as Medtronic, Gore, and Cook generally hold relatively high market shares in the Chinese market.

Meanwhile, with the rapid development of China’s aortic interventional medical device industry, companies such as MicroPort Endovascular and Lifetech Scientific have secured certain market shares. It is anticipated that more enterprises will enter this field in the future, leading to further intensification of market competition.

Percutek Therapeutics stated,Based on a reasonable projection that takes into account factors such as the price-to-research ratio of listed companies in the same industry and the issuer’s most recent financing round, the company estimates its market capitalization will be no less than RMB 1.5 billion. In this highly competitive sector,Will Percutek Therapeutics successfully list on the Beijing Stock Exchange? How will the company continue to solidify its position in the field of vascular intervention in the future? MedDevice Home will continue to monitor these developments.

END

ShangBusiness Cooperation Email: qxzj@landianyiliao.com